Review Article

Efficacy and Safety of Rivaroxaban Compared with Other Therapies Used in Patients with Peripheral Artery Disease Undergoing Peripheral Revascularization: A Systematic Literature Review and Network Meta-Analysis

Table 3

The results of the base case scenario and sensitivity analysis.

Hazard ratios [95% CI] for comparison between RIV+ASA and respective comparators
Base case scenarioSensitivity analysis
ASACLO+ASAVKA+ASADICASACLOCLO+ASAVKAVKA+ASADIC

All-cause deathFE
RE
1.08 [0.92, 1.27]
1.08 [0.00, 245.10]
0.79 [0.42, 1.50]
0.99 [0.00, 1241.02]
0.77 [0.57, 1.04]
0.77 [0.00, 1621.02]
3.788
4.491
1.02 [0.90, 1.17]
1.01 [0.54, 1.83]
No data for comparator1.08 [0.81, 1.42]
1.02 [0.41, 2.38]
1.00 [0.80, 1.26]
0.99 [0.34, 2.78]
0.84 [0.66, 1.06]
0.83 [0.35, 1.95]
1.704
1.832
CV deathFE
RE
1.14 [0.93, 1.40]
1.14 [0.00, 582.71]
0.77 [0.37, 1.60]
0.77 [0.00, 5617.07]
No data for comparator1.117
1.140
1.04 [0.87, 1.24]
1.00 [0.17, 5.56]
1.34 [0.97, 1.84]
1.28 [0.06, 26.01]
1.04 [0.73, 1.47]
0.93 [0.07, 9.48]
1.11 [0.83, 1.48]
1.06 [0.05, 20.50]
1.00 [0.69, 1.46]
0.96 [0.05, 18.43]
1.685
1.295
Ischemic strokeFE
RE
0.87 [0.63, 1.20]
0.87 [0.00, 484.60]
0.30 [0.01, 7.80]
0.30 [0.00, 3557.10]
No data for comparator5.049
5.038
0.77 [0.59, 1.004]
0.72 [0.06, 8.32]
0.77 [0.51, 1.17]
0.73 [0.01, 50.42]
0.91 [0.53, 1.55]
0.76 [0.01, 19.23]
1.53 [0.81, 2.90]
1.43 [0.02, 100.50]
1.20 [0.67 2.14]
1.13 [0.01, 83.53]
8.610
9.004
Any strokeFE
RE
0.94 [0.70, 1.28]
0.94 [0.00, 508.30]
0.92 [0.35, 2.43]
0.93 [0.00, 7213.05]
0.89 [0.50, 1.61]
0.89 [0.00, 6641.02]
3.540
3.543
0.80 [0.62, 1.04]
0.76 [0.30, 1.74]
0.81 [0.54, 1.21]
0.77 [0.16, 3.36]
0.97 [0.61, 1.55]
0.90 [0.23, 2.95]
1.09 [0.66 1.80]
1.03 [0.21, 4.61]
0.78 [0.51 1.19]
0.74 [0.20, 2.44]
5.093
5.814
AmputationFE
RE
0.89 [0.68, 1.16]
0.89 [0.01, 89.00]
1.25 [0.76, 2.07]
1.19 [0.00, 331.20]
No data for comparator1.795
3.019
0.80 [0.63, 1.02]
0.75 [0.26, 1.85]
No data for comparator1.13 [0.73, 1.76]
1.03 [0.25, 3.37]
0.89 [0.62, 1.28]
0.84 [0.15, 4.12]
1.20 [0.48, 3.05]
1.13 [0.17, 6.44]
5.918
6.952
Myocardial infarctionFE
RE
0.88 [0.70, 1.12]
0.89 [0.00, 475.10]
1.09 [0.42, 2.85]
1.11 [0.00, 8665.02]
0.69 [0.40, 1.19]
0.70 [0.00, 4836.02]
2.976
2.998
0.84 [0.69, 1.02]
0.83 [0.40, 1.69]
1.34 [0.93, 1.92]
1.32 [0.37, 4.59]
1.29 [0.84, 1.96]
1.24 [0.40, 3.45]
1.22 [0.73, 2.05]
1.20 [0.33, 4.41]
0.88 [0.62, 1.25]
0.84 [0.29, 2.25]
2.441
3.948
Peripheral revascularizationFE
RE
0.88 [0.79, 0.99]
0.88 [0.00, 189.60]
1.04 [0.75, 1.46]
1.44 [0.00, 1401.00]
No data for comparator2.510
1.765
0.89 [0.81, 0.98]
0.90 [0.42, 1.95]
No data for comparator1.13 [0.88, 1.45]
1.17 [0.51, 4.18]
0.94 [0.80, 1.10]
0.94 [0.25, 3.61]
0.99 [0.63, 1.58]
1.00 [0.25, 3.98]
-2.239
-0.605
Major bleedingFE
RE
1.43 [0.98, 2.11]
1.42 [0.00, 752.41]
0.80 [0.25 2.56]
0.79 [0.00, 5627.25]
0.61 [0.30, 1.24]
0.60 [0.00, 4198.05]
4.727
4.760
1.52 [1.17, 1.98]
1.52 [0.67, 3.45]
No data for comparator1.40 [0.81, 2.43]
1.34 [0.36, 4.14]
0.78 [0.51, 1.17]
0.77 [0.19, 3.10]
0.54 [0.33, 0.89]
0.54 [0.16, 1.74]
4.053
5.770

ASA: aspirin; CLO: clopidogrel; DIC: deviance information criterion; FE: fixed effect; RE: random effect; VKA: vitamin K antagonists. Note: the risk of ALI was not reported in the comparator trials; therefore, the comparison regarding this outcome was not feasible.